CycloLab has four main activities:

We produce sulfobutylether beta-cyclodextrin (SBECD, Dexolve^TM) in multiple ton scale annually under cGMP conditions based on an FDA-approved Drug Master File. A Prezi presentation is describing in detail this operation of CycloLab.
CycloLab operates as a CRO for cyclodextrin related services including:

development of products (pharma, cosmetic, food, agricultural industries),
offering custom synthesis of cyclodextrins, fine-tailored for certain guest molecules (like Sugammadex) or purposes,
performing pilot-scale cGMP compliant manufacturing of cyclodextrins to be used as APIs or excipients in clinical studies or cyclodextrin enabled formulations for the same purpose, and
all analytical tasks related to the above, under GMP (method development, validation, stability studies for formulation ingredients (APIs, cyclodextrins) and final products as well).

CycloLab offers the widest variety of cyclodextrins in various grades (pharma, standard, fine chemical) in a web shop system for various purposes (research, analytics, cell cultures, formulation studies, etc). Besides “regular” derivatives, we always develop something new and special, like maltooligomers, polymers or fluorescent-tagged products.
As an R&D company, we develop next-generation proprietary cyclodextrins and explore potential applications as well. Under our pipeline, you can see the projects and corresponding stages we are currently working on. Interest in collaboration or licensing in these should be communicated to business development

CycloLab is continuously involved in international projects as an industrial partner hosting PhD students and working on inventions and technological improvements. CycloLab is also a pioneer in supporting studies for the novel application of cyclodextrins. The company has been present from the early stage as a consultant in the realization of an application to treat the symptoms of a rare fatal disease, Niemann-Pick type C, a lysosomal storage disorder that strikes people generally before 10 years of age and is incurable. Hydroxypropyl Betadex, applied in the therapy could fundamentally change the standard of living and expand the expected lifespan of patients. This cyclodextrin has recently received an Orphan Drug designation by US FDA and EMA.

As an acknowledgment of exceptional scientific activity, the company has established a prize in honor of József Szejtli in 2013, the world-renowned pioneer and recognized cyclodextrin technologist, founder of CycloLab Cyclodextrin R&D Laboratory Ltd. The prize is presented bi-annually to young cyclodextrin scientists who demonstrate outstanding results in the field of cyclodextrin science and technology.